Cover Image

Transcriptomic and epigenetic landscape of nimorazole-enhanced radiochemotherapy in head and neck cancer

Background - Hypoxia remains a challenge for the therapeutic management of head and neck squamous cell carcinoma (HNSCC). The combination of radiotherapy with nimorazole has shown treatment benefit in HNSCC, but the precise underlying molecular mechanisms remain unclear. - Purpose - To assess and to...

Full description

Saved in:
Bibliographic Details
Main Authors: Besso, María José (Author) , Bitto, Verena (Author) , Koi, Lydia (Author) , Wijaya Hadiwikarta, Wahyu (Author) , Conde-Lopez, Cristina (Author) , Euler-Lange, Rosemarie (Author) , Bonrouhi, Mahnaz (Author) , Schneider, Karolin (Author) , Linge, Annett (Author) , Krause, Mechthild (Author) , Baumann, Michael (Author) , Kurth, Ina (Author)
Format: Article (Journal)
Language:English
Published: October 2024
In: Radiotherapy and oncology
Year: 2024, Volume: 199, Pages: 1-12
ISSN:1879-0887
DOI:10.1016/j.radonc.2024.110348
Online Access:Verlag, kostenfrei, Volltext: https://doi.org/10.1016/j.radonc.2024.110348
Verlag, kostenfrei, Volltext: https://www.sciencedirect.com/science/article/pii/S0167814024006182
Get full text
Author Notes:María José Besso, Verena Bitto, Lydia Koi, Wahyu Wijaya Hadiwikarta, Cristina Conde-Lopez, Rosemarie Euler-Lange, Mahnaz Bonrouhi, Karolin Schneider, Annett Linge, Mechthild Krause, Michael Baumann, Ina Kurth
Description
Summary:Background - Hypoxia remains a challenge for the therapeutic management of head and neck squamous cell carcinoma (HNSCC). The combination of radiotherapy with nimorazole has shown treatment benefit in HNSCC, but the precise underlying molecular mechanisms remain unclear. - Purpose - To assess and to characterize the transcriptomic/epigenetic landscape of HNSCC tumor models showing differential therapeutic response to fractionated radiochemotherapy (RCTx) combined with nimorazole. - Materials/methods - Bulk RNA-sequencing and DNA methylation experiments were conducted using untreated and treated HNSCC xenografts after 10 fractions of RCTx with and without nimorazole. These tumor models (FaDu, SAS, Cal33, SAT and UT-SCC-45) previously showed a heterogeneous response to RCTx with nimorazole. The prognostic impact of candidate genes was assessed using clinical and gene expression data from HNSCC patients treated with primary RCTx within the DKTK-ROG. - Results - Nimorazole responder and non-responder tumor models showed no differences in hypoxia gene signatures However, non-responder models showed upregulation of metabolic pathways. From that, a subset of 15 differentially expressed genes stratified HNSCC patients into low and high-risk groups with distinct outcome. - Conclusion - In the present study, we found that nimorazole non-responder models were characterized by upregulation of genes involved in Retinol metabolism and xenobiotic metabolic process pathways, which might contribute to identify mechanisms of resistance to nitroimidazole compounds and potentially expand the repertoire of therapeutic options to treat HNSCC.
Item Description:Gesehen am 14.02.2025
Physical Description:Online Resource
ISSN:1879-0887
DOI:10.1016/j.radonc.2024.110348

Similar Items